AMGN vs BIIB

For growth investors, Amgen Inc.

(AMGN) is the stronger pick with 9. 9% revenue growth year-over-year, versus 1. 4% for Biogen Inc. (BIIB). Biogen Inc. (BIIB) offers the better valuation at 28. 7x trailing P/E (20. 4x forward), making it the more compelling value choice. Analysts rate Amgen Inc. (AMGN) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Biogen Inc.

(BIIB) is the cheapest at 28. 7x versus Amgen Inc. at 31. 4x. On forward P/E, Amgen Inc. is actually cheaper at 19. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Amgen Inc.

(AMGN) delivered a total return of +134. 8%, compared to -4. 1% for Biogen Inc. (BIIB). Over 10 years, the gap is even starker: AMGN returned +227. 4% versus BIIB's -12. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Biogen Inc.

(BIIB) is the lower-risk stock at 0. 32β versus Amgen Inc. 's 0. 47β — meaning AMGN is approximately 48% more volatile than BIIB relative to the S&P 500. On balance sheet safety, Biogen Inc. (BIIB) carries a lower debt/equity ratio of 38% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Amgen Inc.

(AMGN) is pulling ahead at 9. 9% versus 1. 4% for Biogen Inc. (BIIB). On earnings-per-share growth, the picture is similar: Amgen Inc. grew EPS 88. 2% year-over-year, compared to -21. 1% for Biogen Inc.. Over a 3-year CAGR, AMGN leads at 11. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amgen Inc.

(AMGN) is the more profitable company, earning 21. 0% net margin versus 13. 2% for Biogen Inc. — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMGN leads at 29. 1% versus 19. 1% for BIIB. At the gross margin level — before operating expenses — AMGN leads at 70. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Amgen Inc.

(AMGN) trades at 19. 4x forward P/E versus 20. 4x for Biogen Inc. — 1. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BIIB: -3. 1% to $245. 88.

In this comparison, AMGN (2.

1% yield) pays a dividend. BIIB does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Amgen Inc.

(AMGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 47), 2. 1% yield, +227. 4% 10Y return). Both have compounded well over 10 years (AMGN: +227. 4%, BIIB: -12. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

AMGN pays a dividend while BIIB does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.